Why Jim Cramer Thinks Merck (MRK), Pfizer (PFE), GlaxoSmithKline (GSK) Bids Are Coming After InterMune (ITMN) Deal

NEW YORK (TheStreet) -- TheStreet's Jim Cramer says Roche called its purchase of InterMune  (ITMN) a "bolt-on" acquisition.

Cramer says the $8.3 billion bid signifies that big pharmaceutical companies are thinking big even as Roche calls this a "bolt-on" acquisition. Cramer notes in the old days, "bolt on" would have meant anything less than $1 billion.

Cramer calls this deal important because so many biotech companies are losing money the way InterMune was before it had a breakthrough. His game plan is for a prospective buyer to find a biotech company in stage three, which means it is about to get FDA approval, and looks like it is a need that is unmet.

Must Watch: Jim Cramer Says Roche's "Bolt-On" Acquisition Means Big Pharma is Thinking Big

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Cramer believes bids are coming from Merck  (MRK) , Pfizer  (PFE) and GlaxoSmithKline  (GSK) because they need to do bolt-on acquisitions for growth.

ITMN Chart ITMN data by YCharts

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing